SCHEMBL6300717

SCHEMBL6300717

Cc1cc(C)c2c(c1)[nH]c1cnccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.61
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
CHUK O15111 9/20 0.47
GABRA1 P14867 2/20 0.47
GABRG2 P18507 2/20 0.47
GABRB3 P28472 2/20 0.47
GABRA5 P31644 2/20 0.47
GABRA3 P34903 2/20 0.47
GABRA2 P47869 2/20 0.47
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
IKBKB O14920 2/20 0.47
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
AURKA O14965 1/20 0.47
PIM1 P11309 1/20 0.47
TOP1 P11387 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29986179 0.78 CHUK (0.58) ADORA3ADORA2AADORA1CHUKGABRA1
SCHEMBL7086128 0.78 CHUK (0.58) ADORA3ADORA2AADORA1CHUKGABRA1
SCHEMBL2628365 0.77 ACHE (0.59) ADORA3CHUKGABRA1GABRG2GABRB3
SCHEMBL15985686 0.77 KIF11 (0.55) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL31060553 0.76 ADORA3 (1.00) ADORA3ADORA2AADORA1CHUKGABRA1
SCHEMBL9815402 0.75 KIF11 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29726989 0.75 KIF11 (0.58) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29588654 0.73 GRIN2D (0.48) KDM4EALDH1A1HPGDKIF11POLB
SCHEMBL12396541 0.73 CHUK (0.78) ADORA3ADORA2AADORA1CHUKGABRA1
SCHEMBL30322777 0.73 CHUK (0.78) ADORA3ADORA2AADORA1CHUKGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858622-B2 Cycloalkano-indole and -azaindole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-02-22 US disclosed
EP-0705831-B1 Cycloalkano-indole- and -azaindole derivatives BAYER AG (DE) 2003-12-03 EP disclosed
US-20030149073-A1 Cycloalkano-indole and -azaindole derivatives MULLER ULRICH (DE) 2003-08-07 US disclosed
US-6479503-B2 SUCH AS 2-(S/R)-2-(4-(2,4-DIMETHYL-5,6,7,8-TETRAHYDRO-ALPHA-CARBOLIN-9-YL)METHYL -PHENYL)-2-CYCLOPENTYL-ACETIC ACID N-((R)PHENYLGLYCINOAMIDE) FOR TREATING ATHEROSCLEROSIS BAYER AKTIENGESELLSCHAFT (DE) 2002-11-12 US disclosed
US-20020147209-A1 Cycloalkano-indole and -azaindole derivatives MUELLER ULRICH (DE) 2002-10-10 US disclosed
US-20020055635-A1 Cycloalkano-indole and -azaindole derivatives MULLER ULRICH (DE) 2002-05-09 US disclosed
US-6265431-B1 ANTICHOLESTEROL DRUGS BAYER AKTIENGESELLSCHAFT (DE) 2001-07-24 US disclosed
US-6245775-B1 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2001-06-12 US disclosed
US-5684014-A FOR TREATING ATHEROSCLEROSIS BAYER AKTIENGESELLSCHAFT (DE) 1997-11-04 US disclosed
EP-0705831-A2 Cycloalkano-indole- and -azaindole derivatives BAYER AG (DE) 1996-04-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149073-A1 Cycloalkano-indole and -azaindole derivatives AADAC, IDO1, AADAT ADORA3 148/4885ADORA2A 67/4885ADORA1 231/4885
US-20020147209-A1 Cycloalkano-indole and -azaindole derivatives AADAC, IDO1, AADAT ADORA3 148/4885ADORA2A 67/4885ADORA1 231/4885
US-20020055635-A1 Cycloalkano-indole and -azaindole derivatives ADRB3, AADAT, INMT ADORA3 25/4885ADORA2A 77/4885ADORA1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.